The government of India vide notification dated March 10, 2016, has prohibited the manufacture for sale and distribution of cough syrup Corex with immediate effect.
Pfizer�s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial
The company had high hopes on this already existing FDA approved drug Lyrica. But it has showed efficacy equal to only that of the placebo.
The company had high hopes on this already existing FDA approved drug Lyrica. But it has showed efficacy equal to only that of the placebo.
‘Corex has a well established efficacy and safety profile in India for more than 30 years. Pharmaceutical company Pfizer is exploring all available options at its disposal.’
"In view of this, the company has discontinued the manufacture and sale of its drug Corex with immediate effect," it added. The company said that Corex has a well established efficacy and safety profile in India for more than 30 years. "The company is exploring all available options at its disposal." Regarding the impact of discontinuation of this syrup on the company, the statement said: "The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. It may be noted that Corex recorded sale of Rs.176 crore for the nine-month period ended December 31, 2015."
Source-IANS
Pharmaceutical Company Pfizer To Shut Down its' Navi Mumbai Plant From September
There has been zero production from this plant since 2013. So the closure will not affect availability of medicines in the market.
There has been zero production from this plant since 2013. So the closure will not affect availability of medicines in the market.
Pfizer Stops Sale of Prevnar Vaccine for Children in China, No Explanations Given
The Prevenar vaccine helped prevent infections such as pneumonia, which killed an estimated 935,000 children under the age of five globally in 2013.
The Prevenar vaccine helped prevent infections such as pneumonia, which killed an estimated 935,000 children under the age of five globally in 2013.
US Pharma Giant Pfizer Takes Over $17 Billion Hospira
US pharmaceutical giant Pfizer will expand its line of drugs and therapies with the takeover of $17 billion Hospira.
US pharmaceutical giant Pfizer will expand its line of drugs and therapies with the takeover of $17 billion Hospira.
